Your browser doesn't support javascript.
loading
Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change.
Bermudez, Camilo; Graff-Radford, Jonathan; Syrjanen, Jeremy A; Stricker, Nikki H; Algeciras-Schimnich, Alicia; Kouri, Naomi; Kremers, Walter K; Petersen, Ronald C; Jack, Clifford R; Knopman, David S; Dickson, Dennis W; Nguyen, Aivi T; Reichard, R Ross; Murray, Melissa E; Mielke, Michelle M; Vemuri, Prashanthi.
Afiliação
  • Bermudez C; Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA. bermudeznoguera.camilo@mayo.edu.
  • Graff-Radford J; Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA.
  • Syrjanen JA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Stricker NH; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
  • Algeciras-Schimnich A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Kouri N; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Kremers WK; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • Petersen RC; Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA.
  • Jack CR; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
  • Knopman DS; Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55902, USA.
  • Dickson DW; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Nguyen AT; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Reichard RR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Murray ME; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Mielke MM; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Vemuri P; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Acta Neuropathol ; 146(1): 13-29, 2023 07.
Article em En | MEDLINE | ID: mdl-37269398
ABSTRACT
While plasma biomarkers for Alzheimer's disease (AD) are increasingly being evaluated for clinical diagnosis and prognosis, few population-based autopsy studies have evaluated their utility in the context of predicting neuropathological changes. Our goal was to investigate the utility of clinically available plasma markers in predicting Braak staging, neuritic plaque score, Thal phase, and overall AD neuropathological change (ADNC).We utilized a population-based prospective study of 350 participants with autopsy and antemortem plasma biomarker testing using clinically available antibody assay (Quanterix) consisting of Aß42/40 ratio, p-tau181, GFAP, and NfL. We utilized a variable selection procedure in cross-validated (CV) logistic regression models to identify the best set of plasma predictors along with demographic variables, and a subset of neuropsychological tests comprising the Mayo Clinic Preclinical Alzheimer Cognitive Composite (Mayo-PACC). ADNC was best predicted with plasma GFAP, NfL, p-tau181 biomarkers along with APOE ε4 carrier status and Mayo-PACC cognitive score (CV AUC = 0.798). Braak staging was best predicted using plasma GFAP, p-tau181, and cognitive scores (CV AUC = 0.774). Neuritic plaque score was best predicted using plasma Aß42/40 ratio, p-tau181, GFAP, and NfL biomarkers (CV AUC = 0.770). Thal phase was best predicted using GFAP, NfL, p-tau181, APOE ε4 carrier status and Mayo-PACC cognitive score (CV AUC = 0.754). We found that GFAP and p-tau provided non-overlapping information on both neuritic plaque and Braak stage scores whereas Aß42/40 and NfL were mainly useful for prediction of neuritic plaque scores. Separating participants by cognitive status improved predictive performance, particularly when plasma biomarkers were included. Plasma biomarkers can differentially inform about overall ADNC pathology, Braak staging, and neuritic plaque score when combined with demographics and cognitive variables and have significant utility for earlier detection of AD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Alzheimer Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Acta Neuropathol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos